Core Viewpoint - Hims & Hers Health, Inc. is experiencing a decline in stock price, with upcoming earnings expected to show significant year-over-year growth in both earnings and revenue [1][2][3]. Financial Performance - The company plans to announce its earnings on November 3, 2025, with analysts expecting earnings of $0.09 per share, representing a 50% year-over-year growth [2]. - The Zacks Consensus Estimate for revenue is projecting net sales of $583.68 million, up 45.35% from the previous year [2]. - Full-year estimates call for earnings of $0.59 per share and revenue of $2.35 billion, indicating year-over-year changes of +118.52% and +59.39%, respectively [3]. Analyst Estimates - Recent changes to analyst estimates reflect evolving short-term business trends, with positive revisions indicating a favorable outlook on the company's health and profitability [4]. - The consensus EPS projection has moved 1.63% lower in the past 30 days, and the company currently holds a Zacks Rank of 3 (Hold) [6]. Valuation Metrics - Hims & Hers Health, Inc. has a Forward P/E ratio of 83.89, which is a premium compared to the industry average Forward P/E of 41.13 [7]. - The company's PEG ratio is currently 3.42, compared to the Medical Info Systems industry's average PEG ratio of 3.34 [7]. Industry Context - The Medical Info Systems industry, part of the Medical sector, has a Zacks Industry Rank of 88, placing it within the top 36% of over 250 industries [8]. - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8].

Core Insights - Hims & Hers Health, Inc. is enhancing its healthcare services through artificial intelligence, data infrastructure, and personalized treatment pathways, aiming to create a next-generation healthcare experience [1][7] - The appointment of Mo Elshenawy as CTO is a significant move towards AI-driven automation and intelligent diagnostics, aligning with the company's vision for global personalized care [2] - Recent product launches, including personalized oral testosterone and menopause care, utilize data-driven models to tailor treatments to individual patient needs [3] Company Developments - Hims & Hers has initiated an $870 million convertible notes offering to boost investments in data infrastructure and personalized treatment technologies [2] - The company has reported a 104.1% increase in share price year-to-date, outperforming the industry growth of 28.2% [6] Financial Performance - Hims & Hers has a forward 12-month price-to-sales ratio of 4.1X, which is lower than the industry average of 5.9X but higher than its three-year median of 2.5X [9] - The Zacks Consensus Estimate for Hims & Hers' earnings per share in 2025 indicates a 118.5% improvement from 2024 [9]

Core Insights - Hims & Hers Health, Inc. launched a new specialty in women's health focusing on affordable treatment plans for women experiencing perimenopause and menopause [1][5] - The launch is expected to enhance Hims & Hers' business and solidify its position in the niche market [2][7] Company Developments - Following the announcement, Hims & Hers' shares declined nearly 4.9% [3] - The company currently has a market capitalization of $11.25 billion and an earnings yield of 1.2%, which is better than the industry's negative yield [4] - Hims & Hers estimates that women spend an average of nine years in poor health, which is 25% more than men, impacting their work and community presence [5] - Approximately 1.3 million women in the U.S. experience menopause annually, but only 30% of OB/GYN residency programs provide formal menopause training [5] - Hims & Hers serves over half a million subscribers and aims to surpass $1 billion in annual revenues by 2026 [5][6] Market Potential - The global menopause market is projected to grow from $17.79 billion in 2024 to $24.35 billion by 2030, with a CAGR of approximately 5.4% [7] - The latest product launch is anticipated to significantly boost Hims & Hers' business due to favorable industry trends [7] Stock Performance - Hims & Hers shares have increased by 117.7% over the past year, outperforming the industry and the S&P 500 [10]

Core Viewpoint - Healthcare and telemedicine stocks, particularly Hims & Hers Health, have been significant market winners due to increasing demand for virtual care and wellness solutions, but recent events have raised concerns about the company's future performance [1][2]. Company Overview - Hims & Hers Health is a prominent player in digital healthcare, connecting users to licensed medical professionals through its telehealth platform, offering treatments in various areas including mental health and sexual wellness [3]. - The company has experienced substantial growth, with its stock surging 109% year-to-date, driven by internal momentum and product expansion [4]. Recent Developments - CEO Andrew Dudum's sale of approximately $11 million in stock has led to a more than 10% drop in shares, raising concerns about the company's stability amid regulatory issues and pricing pressures on GLP-1 generics [2]. - Hims & Hers has introduced a Menopause and Perimenopause specialty within its "Hers" division, aiming to drive revenue past $1 billion by 2026, which could account for over a third of total sales [6]. Financial Metrics - The company's current valuation appears challenging, with a price-to-book (P/B) ratio of 22, significantly higher than the sector median of 3, indicating the stock is expensive [5]. - The EV/EBITDA ratio stands at 76, well above the sector median of 14, suggesting that Hims & Hers is trading at a substantial premium [5].

Core Viewpoint - The company Hims & Hers Health, Inc. is perceived as undervalued by the market, which has led to a bullish outlook on its stock performance [1]. Group 1: Investment Strategy - The investment strategy involves a balanced portfolio of low-cost funds and individual stocks, with a focus on long-term holding of at least 10 years [1]. - The analyst emphasizes the importance of understanding market behavior beyond numerical valuations, viewing the market as a meeting point of demand and supply [1]. Group 2: Current Position and Performance - The analyst holds a position in Hims valued at approximately $10,000, having previously realized a gain of over 50% on the original investment [3]. - The intention is to maintain the remaining position for the long term, with potential additions during market weaknesses [3].

Core Viewpoint - The company Hims & Hers Health, Inc. (NYSE: HIMS) is perceived as undervalued by the market, which has led to a bullish outlook on its stock performance [1]. Group 1: Investment Strategy - The investment strategy involves a balanced portfolio of low-cost funds and individual stocks, with a focus on long-term holding of at least 10 years [1]. - The analyst emphasizes the importance of understanding market behavior beyond numerical valuations, viewing the market as a meeting point of demand and supply [1]. Group 2: Current Position and Performance - The analyst holds a position in HIMS valued at approximately $10,000, having previously realized a gain of over 50% on the original investment [3]. - The intention is to maintain the remaining position for the long term, with potential additions during market weaknesses [3].

Core Insights - The article emphasizes the importance of identifying deeply undervalued equities with long-term potential that are often overlooked by the market [1] Group 1: Investment Strategy - The focus is on managing investments since 1999, which provides a perspective across multiple market cycles [1] - The analyst has a background in Economics and is pursuing CFA certification, indicating a strong foundation in financial analysis [1] Group 2: Market Perspective - The article suggests that there are significant opportunities in the market for undervalued stocks that may not be recognized by the broader investment community [1]

If you'd like to learn more about how to best position yourself in under valued stocks mispriced by the market to start Q4, consider joining Out Fox The Street .Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in HIMS over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not r ...

Group 1 - The article discusses the potential for investing in undervalued stocks that are mispriced by the market as Q4 approaches [1] - It suggests that investors may consider joining a specific service to gain insights on these investment opportunities [1] Group 2 - There is a mention of a potential long position in HIMS, indicating a possible interest in this stock within the next 72 hours [2] - The article emphasizes that the opinions expressed are those of the author and not influenced by any compensation from companies mentioned [2] Group 3 - The information provided is intended for informational purposes only and does not constitute a solicitation to buy or sell securities [3] - It highlights the importance of conducting personal research or consulting a financial advisor before making investment decisions [3]

Key Points - NIO-SW (09866) rose over 4% as CEO Li Bin emphasized the necessity of achieving profitability in Q4 during an internal meeting on October 17 [1] - COSCO Shipping Energy (01138) increased over 4% due to successful capital increase enhancing future shipping capacity and strategic value in international shipping competition [1] - Datang New Energy (01798) fell over 4% despite a more than 10% increase in power generation in the first nine months, influenced by adjustments in VAT policies for wind power [1] - Laopuhuang Gold (06181) dropped over 6%, although it still recorded a cumulative increase of over 10% this month, with a price adjustment announcement set for October 26 [1] - Jitu Express-W (01519) rose over 3% as Q3 parcel volume exceeded market expectations, with anti-involution policies likely to restore company profits [1] - JD Health (06618) increased over 4% as institutions expect enhanced drug sales to benefit overall gross margin [1] - Derin Holdings (01709) rose over 3% after announcing plans to acquire 2,995 BM mining machines from Bitmain, strengthening its Bitcoin mining business [1] - Sanhua Intelligent Control (02050) increased over 6% after announcing an increase in the share repurchase price limit, with recent catalysts in the robotics sector [1] - Bilibili-W (09626) rose over 3% as Q3 advertising performance is expected to continue, with a new card game set to contribute additional revenue early next year [1] - Alibaba-W (09988) rose over 4% after partnering with Ant Group to acquire a 13-story commercial building in Causeway Bay for HKD 7.2 billion [2] US Market Highlights - CSX Transportation (CSX.US) rose 1.69% as CEO Steve Angel indicated a focus on strategic opportunities and reevaluating aspects of railroad operations [3] - Novo Nordisk (NVO.US) fell 3.07% and Eli Lilly (LLY.US) dropped 2.02% following Trump's comments on potential price reductions for the weight loss drug Ozempic [3] - American Lithium (LAC.US) fell 8.12% after JPMorgan downgraded its rating from "neutral" to "underweight," citing overvaluation concerns [3] - Ford Motor Company (F.US) rose 1.53% as the NHTSA announced a recall of nearly 625,000 vehicles due to safety issues [3] - ASE Technology Holding (ASX.US) continued to rise 1.11% with the expansion of its K18B advanced packaging plant expected to commence production in Q1 2028 [3] - NetEase (NTES.US) fell 0.26% after announcing the discontinuation of its mobile game "The Lord of the Rings: Rise to War" [3] - Oracle (ORCL.US) fell 6.93% as it projected a 35% gross margin for its AI infrastructure plans during the Oracle AI World conference [4] - Hims & Hers Health (HIMS.US) dropped 15.84% after launching affordable treatment options for perimenopausal and menopausal individuals [4] - Gold stocks generally declined, with Harmony Gold (HMY.US) down 8.86% and Kinross Gold (KGC.US) down 8.99%, amid a significant drop in spot gold prices [4]